Influenza Pipeline: Advancing Innovation with 120+ Trailblazers Developing Transformative Therapies | DelveInsight

The Influenza market is rapidly advancing and is fueled by groundbreaking research and innovative therapies from companies such as AlloVir, Cocrystal Pharma, Poolbeg Pharma, and Ridgeback Biotherapeutics. These industry pioneers are transforming treatment strategies and redefining the future of Influenza, bringing new hope to patients worldwide.

DelveInsight's "Influenza Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Influenza market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.

For emerging Influenza drugs, the Influenza pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Influenza Pipeline Report
• DelveInsight's Influenza Pipeline analysis depicts a robust space with 120+ active players working to develop 120+ pipeline drugs for Influenza treatment.
• The leading Influenza companies include Cidara Therapeutics, SAb Biotherapeutics, FluGen, Moderna, Vir Biotechnology, Vaxart, Emergo Therapeutics, AlloVir, Cocrystal Pharma, Poolbeg Pharma, Ridgeback Biotherapeutics, Viriom, NanoViricides, Evrys Bio, ETHRIS, Kino Pharma, and others are evaluating their lead assets to improve the Influenza treatment landscape.
• Key Influenza pipeline therapies in various stages of development include CD388, SAB-176, M2SR, mRNA-1010, VIR-2482, VXA-A1.1, ALVR106, CC-42344, POLB 001, LAGEVRIO, AV5124, FluCide (Injectable), FluCide (Oral), ETH 47, and others.
• In Feb 2025, a scheduled FDA vaccine advisory committee meeting to select strains for next season's flu shot was canceled, as confirmed by committee member Dr. Paul Offit. Federal health officials notified members of the cancellation via email.
• In November 2024, Novavax (Nasdaq: NVAX) announced that the U.S. FDA has lifted the clinical hold on its Investigational New Drug (IND) application for the COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine candidates.
• In Sept 2024, FluMist was approved in the US as the only self-administered influenza vaccine. This needle-free nasal spray can be self-administered by adults up to 49 years old or given by a parent/caregiver to those aged 2-17. The FDA's approval was based on a study showing adults could successfully self-administer or administer FluMist to others.

Request a sample and discover the recent breakthroughs happening in the Influenza pipeline landscape @ https://www.delveinsight.com/report-store/influenza-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Influenza Overview
Influenza is a highly contagious airborne disease that spreads seasonally, causing acute febrile illness with symptoms ranging from mild fatigue to severe respiratory failure and death. It leads to significant morbidity, lost workdays, and mortality. During the 2019-2020 season, the CDC estimated that seasonal influenza caused between 24,000 and 62,000 deaths, while data for the 2020-2021 season was insufficient for an estimate. The highest mortality rates are seen in infants and the elderly.
Traditionally, influenza diagnosis is based on clinical symptoms, though rapid diagnostic tests with high specificity but moderate sensitivity are increasingly used. The gold standard remains viral culture from nasopharyngeal or throat samples. In elderly or high-risk patients with pulmonary symptoms, chest radiography may be performed to rule out pneumonia.
Vaccination remains the most effective prevention strategy. The CDC evaluates global influenza trends annually to adjust vaccine subtypes as needed. Initially, the trivalent vaccine provided protection against three strains (A-H1, A-H3, and B). In 2012, the quadrivalent vaccine, covering an additional B strain, was approved and introduced for the 2013-2014 flu season. Since the 2021-2022 season, all flu vaccines have been quadrivalent.

Find out more about Influenza medication @ https://www.delveinsight.com/report-store/influenza-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Influenza Treatment Analysis: Drug Profile
mRNA-1010: Moderna
mRNA-1010 is an investigational vaccine designed to encode hemagglutinin (HA) glycoproteins from the four influenza strains recommended by the World Health Organization (WHO), including influenza A/H1N1, A/H3N2, and influenza B/Yamagata- and B/Victoria-lineages. HA, a key surface glycoprotein of the influenza virus, is the primary target of current influenza vaccines and plays a crucial role in generating broad protection. mRNA-1010 is currently in Phase III clinical trials for the prevention of seasonal influenza.

SAB-176: SAB Biotherapeutics
SAB-176 is a quadrivalent, fully human, broadly neutralizing polyclonal antibody therapy in development for the treatment of severe seasonal influenza in hospitalized patients. Developed using the DiversitAbTM platform, it is designed to specifically target both Type A and Type B influenza viruses. Preclinical data suggest that SAB-176 provides broad protection against multiple influenza strains. This potent polyclonal antibody therapy may help treat severely ill patients and offer protective immunity for high-risk populations, such as the elderly and immunocompromised individuals.

INNA-051: ENA Respiratory Pty Ltd
INNA-051 is a nasal spray-based, broad-spectrum antiviral immunomodulator under clinical development for pre- and post-exposure prophylaxis against respiratory viral infections. Its mechanism of action and nasal route of administration allow it to target multiple respiratory viruses across diverse patient populations, including those with underlying health conditions. INNA-051 is currently being evaluated in a Phase 2a influenza-challenge study in healthy volunteers.

Key Influenza Therapies and Companies
• CD388 - Cidara Therapeutics
• SAB-176 - SAb Biotherapeutics
• INNA-051 - ENA Respiratory Pty Ltd
• M2SR - FluGen
• mRNA-1010 - Moderna
• VIR-2482 - Vir Biotechnology
• VXA-A1.1 - Vaxart
• ALVR106 - AlloVir
• CC-42344 - Cocrystal Pharma
• POLB 001 - Poolbeg Pharma
• LAGEVRIO - Ridgeback Biotherapeutics
• AV5124 - Viriom
• FluCide (Injectable) - NanoViricides
• FluCide (Oral) - NanoViricides
• Research Program: Sirtuin Targeted Therapeutics for Respiratory Viral Infections - Evrys Bio
• ETH 47 - ETHRIS

Learn more about the novel and emerging Influenza pipeline therapies @ https://www.delveinsight.com/report-store/influenza-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Influenza Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

By Molecule Type
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Scope of the Influenza Pipeline Report
• Coverage: Global
• Key Influenza Companies: Cidara Therapeutics, SAb Biotherapeutics, FluGen, Moderna, Vir Biotechnology, Vaxart, Emergo Therapeutics, AlloVir, Cocrystal Pharma, Poolbeg Pharma, Ridgeback Biotherapeutics, Viriom, NanoViricides, Evrys Bio, ETHRIS, Kino Pharma, and others.
• Key Influenza Pipeline Therapies: CD388, SAB-176, M2SR, mRNA-1010, VIR-2482, VXA-A1.1, ALVR106, CC-42344, POLB 001, LAGEVRIO, AV5124, FluCide (Injectable), FluCide (Oral), ETH 47, and others.

Dive deep into rich insights for drugs used for Influenza treatment; visit @ https://www.delveinsight.com/report-store/influenza-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Influenza Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Influenza Pipeline Therapeutics
6. Influenza Pipeline: Late-Stage Products (Phase III)
7. Influenza Pipeline: Late-Stage Products (Phase III)
8. Influenza Pipeline: Mid-Stage Products (Phase II)
9. Influenza Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.